To the Editor.—
Bissette and colleagues1 have reported reduced concentrations of somatostatin immunoreactivity (somatostatin-I) in the cerebrospinal fluid (CSF) from depressed patients (and those with other psychiatric diagnoses) compared with controls, confirming the report by Rubinow and colleagues.2 However, it is not clear whether this reduction reflects an alteration in somatostatin concentration in the brain. We have measured somatostatin-I concentrations in the brains of depressed suicides and controls.
Subjects and Methods.—
Depression was diagnosed retrospectively in 12 suicide subjects using the criteria of Beskow and colleagues3 (group 1, endogenous depression; group 2, depressive syndrome in the absence of other psychiatric disorders). Causes of death were carbon monoxide poisoning (n = 4), hanging (n = 4), and drug overdose (n = 4). For comparison, 12 ageand sex-matched controls who died of natural causes (principally myocardial infarction) were also studied. There was no significant difference in delay from death to postmortem examination
Charlton BG, Wright C, Leake A, et al. Somatostatin Immunoreactivity in Postmortem Brain From Depressed Suicides. Arch Gen Psychiatry. 1988;45(6):597. doi:10.1001/archpsyc.1988.01800300095015
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.